Major Research Project RP006
Collaborating Institution: The University of Texas Medical Branch (UTMB), Galveston, TX
Principal Investigator: Alfredo Torres, PhD
Title of the Project: Vaccine Development for Burkholderia mallei and B. pseudomallei
- Janice Endsley, PhD – UTMB, Galveston, TX
- Katherine Brown, PhD – University of Texas at Austin, Austin, TX
- Richard Titball, BSc, PhD, DSc, FRCPath – University of Exeter, Devon, UK
Web page: http://biosciences.exeter.ac.uk/staff/index.php?web_id=rick_titball
- Chad Roy, PhD – Tulane University Health Sciences Center, Tulane National Primate Research Center (TNPRC), Covington, LA
- Andrew Lackner, DVM, PhD – TNPRC, Covington, LA
Expected Product: Development of prophylactic vaccines for the category B agents Burkholderia pseudomallei and B. mallei.
Description: This project is directed towards the development of vaccines for the category B agents Burkholderia pseudomallei and Burkholderia mallei. There is an urgent and acknowledged need to develop better prophylactic countermeasures using vaccines and immune stimulants for both melioidosis and glanders. We believe it is appropriate to consider these pathogens in parallel in this project because they are closely related at a genetic level, and there is a possibility that common approaches to these diseases can be identified. The aims of this project are to:
- Identify optimal delivery systems and protein carriers.
- Develop optimized protein-polysaccharide conjugation methods.
- Compare efficacy of homologous versus heterologous protein–polysaccharide conjugates.
- Identify biomarkers and mechanisms of vaccine-mediated protection in acute disease models, including the laboratory mouse, the humanized SCID mouse, and nonhuman primate models.
Our principal goal is to devise a non-living vaccine that is able to protect against both B. pseudomallei and B. mallei infection. This is an important consideration for eventual licensure and use with potential applications for special populations such as young children, the elderly, pregnant women, and immunocompromised subjects. Ultimately, the studies outlined in this proposal will establish a data set to begin the process of a successful submission of an investigative new drug (IND) application to the Food and Drug Administration.